Skip to content

Gluteal Turnover Flap for Closure of the Perineal Wound After Abdominoperineal Resection for Rectal Cancer

Gluteal Turnover Flap for Closure of the Perineal Wound After Abdominoperineal Resection for Rectal Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04004650
Acronym
BIOPEX2
Enrollment
160
Registered
2019-07-02
Start date
2019-06-28
Completion date
2022-11-01
Last updated
2019-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominoperineal Resection, Rectal Cancer, Wound Heal

Brief summary

Background: About 700 patients per year undergo an abdominoperineal resection (APR) for distal rectal cancer (Dutch Colorectal Audit 2016).Neoadjuvant (chemo)radiotherapy is often used to further improve locoregional control. Morbidity after APR is substantial and mainly consisting of perineal wound problems in about 35% of the patients. lf primary healing of the perineal wound after APR doesn't occur, secondary healing can take up to one year, and there is even a small proportion of patients in whom a chronic perineal wound or fistula persists after one year. During this long period, intensive wound care is necessary. This results in a heavy burden on both patient and health care resources. Objective: The high morbidity rate of the perineal wound has resulted in a continuing discussion on how to close the perineal defect after APR. Our research group recently published the BIOPEX-study (NL42094.018.12), in which 104 patients were randomized between primary perinea! wound closure and biological mesh closure of the pelvic floor after APR with preoperative radiotherapy for rectal cancer. Similar uncomplicated perineal wound healing rate at 30 days (Southampton wound score \< 2) was found: 63% versus 66%, respectively. The hypothesis behind this negative trial result is related to the perineal dead space between the skin and the biological mesh. Fluid will accumulate in this dead space with the risk of secondary contamination and abscess formation, leading to wound dehiscence and purulent discharge. Autologous tissue flaps have been suggested to improve perineal wound healing based on several cohort studies. At least in the Netherlands, these flaps are used only for selected patients with the large defects and highest risk of wound problems, because of the more extensive surgery with added surgical trauma and operative time, and associated donor site morbidity. For these reasons, primary perineal closure (control arm of BIOPEX) is still the standard of care in the Netherlands. A gluteal turnover flap (GT flap) is a small transposition flap trom the unilateral adjacent perineal skin and subcutaneous fat, which is flipped into the perineal dead space, and stitched with the de-epithelialised dermis to the contralateral pelvic floor remnant. Subsequently, the perineal subcutaneous fat and skin are closed over the flap in the midline, thereby not adding a donor site scar. A small pilot study trom our group showed that this is a promising solution for routine perineal closure after APR. Study design: In this multicenter single blinded study, eligible patients will be randomized between pelvic floor reconstruction using a GT flap (intervention arm) and primary closure of the perineal defect (standard arm). The perineal wound healing will be evaluated at 14 days and 1, 3, and 6 months post-operatively using the Southampton wound scoring system by an independent observer.

Interventions

PROCEDUREGluteal turnover flap

Link to procedure: https://www.youtube.com/watch?v=u7\_vH2\_1ZZc

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* clinical diagnosis of primary rectal cancer or recurrent rectal cancer * scheduled for abdominalperineal resection * older then 18 years

Exclusion criteria

* intersphincteric APR * (biological) mesh placement * extended resections (sacral resection except for coccyx resection, (posterior) exenteration) * severe systemic diseases affecting wound healing except diabetes (i.e. renal failure requiring dialysis, liver cirrhosis, and immune compromised status like HIV), collagen disorders (i.e. Marfan) * enrolment in other trials with overlapping primary endpoint.

Design outcomes

Primary

MeasureTime frameDescription
Perineal wound healing rate 30 days30 daysThe primary endpoint of the study is the percentage of uncomplicated perineal wound healing defined as a Southampton wound score of less than Il at 30 days postoperatively.

Secondary

MeasureTime frameDescription
Re-intervention or re-admission rate1,3,6 monthsNeed tor re-intervention or re-admission related to pre-sacral abscess or either perineal wound problems.
Perineal hernia rate1,3,6 monthslncidence of symptomatic and asymptomatic perineal hernia
Health-related quality of life1,3,6 monthsquestionnaires: The 5-level EQ-5D version (EQ-5D-5L)
Quality of Life in cancer patients1,3,6 monthsquestionnaires: European Organization for Research and Treatment for Cancer Quality of Life Questionnaire (C30-QL2, CR29)
Perineal wound healing14 days, 3 and 6 months postoperativelySouthampton wound score
Urogenital Distress1,3,6 monthsquestionnaires: Urogenital Distress Inventory (UDI-6)
Incontinence scale1,3,6 monthsquestionnaires:Incontinence Impact Questionnaire short form (IIQ-7)
Urogenital function1,3,6 monthsquestionnaires: international index of erectile function (IIEF)
Female sexual distress1,3,6 monthsquestionnaires: Female sexual distress scale (FSDS-R)
Generic quality of Life3,6 monthsquestionnaires: Short Form Survey (SF36)

Countries

Netherlands

Contacts

Primary ContactSarah Sharabiany, MD
s.sharabiany@amsterdamumc.nl0031653663288
Backup ContactGijsnert Musters, MD, PhD
g.d.musters@amsterdamumc.nl

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026